

## Contents

**Foreword** *XIII*

**List of Contributors** *XV*

<b>1</b>	<b>Analytical Validation within the Pharmaceutical Lifecycle</b>	<i>1</i>
	<i>Phil Nethercote and Joachim Ermer</i>	
1.1	Development of Process and Analytical Validation Concepts	<i>1</i>
1.2	Alignment between Process and Analytics: Three-Stage Approach	<i>4</i>
1.3	Predefined Objectives: Analytical Target Profile	<i>5</i>
1.4	Analytical Life Cycle	<i>8</i>
	References	<i>9</i>
<b>2</b>	<b>Analytical Instrument Qualification</b>	<i>11</i>
2.1	Analytical Instrument and System Qualification	<i>11</i>
	<i>Christopher Burgess and R. D. McDowall</i>	
2.1.1	Data Quality and Integrity in a GMP Environment	<i>11</i>
2.1.1.1	Criteria for Quality Data	<i>11</i>
2.1.1.2	Regulatory Rationale for Qualified Analytical Instruments	<i>12</i>
2.1.2	USP General Chapter <1058>	<i>12</i>
2.1.2.1	Data Quality Triangle	<i>14</i>
2.1.2.2	Analytical Instrument Qualification Life Cycle: the Four Qs Model	<i>14</i>
2.1.2.3	Risk-Based Classification of Apparatus, Instruments, and Systems	<i>15</i>
2.1.2.4	Roles and Responsibilities for AIQ	<i>17</i>
2.1.2.5	Software Validation for Group B and C Systems	<i>18</i>
2.1.3	Enhancement of <1058> and Harmonization of a Risk-Based Approach to Instruments and Systems with GAMP Laboratory GPG Second Edition	<i>18</i>
2.1.3.1	Increased Granularity of USP <1058> Groups	<i>18</i>
2.1.3.2	Clarification of AIQ Terminology	<i>19</i>
2.1.3.3	A Continuum of Analytical Apparatus, Instruments, and Systems	<i>19</i>

2.1.3.4	Mapping USP <1058> Instrument Groups to GAMP Software Categories	20
2.1.3.5	Enhanced Data Quality Triangle	20
2.1.4	Risk-Based Approaches to Analytical Instrument and System Qualification	20
2.1.4.1	Expanded <1058> Instrument and System Categories	23
2.2	Efficient and Economic HPLC Performance Qualification	25
	<i>Hermann Wätzig</i>	
2.2.1	Introduction	25
2.2.1.1	The Importance of Analytical Instrument Qualification	25
2.2.1.2	Terms and Definitions	25
2.2.1.3	Continuous Performance Qualification: More by Less	27
2.2.2	Development of the Revised OQ/PQ Parameters List	27
2.2.3	Transfer of Modular Parameters into the Holistic Approach	29
2.2.3.1	Autosampler	29
2.2.3.2	Solvent Delivery System	29
2.2.3.3	Detector	30
2.2.4	OQ/PQ Data in Comparison with SST Data	32
2.2.5	Control Charts	33
2.2.6	General Procedure for Continuous PQ	34
2.2.7	Concluding Remarks	36
	Acknowledgment	37
	Abbreviations	37
	References	38
<b>3</b>	<b>Establishment of Measurement Requirements – Analytical Target Profile and Decision Rules</b>	<b>41</b>
	<i>Mary Lee Jane Weitzel</i>	
3.1	Introduction	41
3.2	Defining the Fitness for Intended Use	42
3.3	Decision Rules	42
3.4	Overview of Process to Develop Requirements for Procedure Performance	43
3.5	Decision Rules and Compliance	43
3.6	Calculating Target Measurement Uncertainty	45
3.6.1	Coverage Factor, k, and Data Distributions	46
3.7	Types of Decision Rules	47
3.7.1	Decision Rules That Use Guard Bands	48
3.8	Target Measurement Uncertainty in the Analytical Target Profile	49
3.8.1	Cost of Analysis	49
3.9	Bias and Uncertainty in a Procedure	50
3.10	ATP and Key Performance Indicators	51
3.11	Measurement Uncertainty	51
3.11.1	What Uncertainty Is	51
3.11.2	Reporting Measurement Uncertainty	52

3.11.3	How Uncertainty is Estimated	54
3.11.4	Uncertainty Contains All Sources of Random Variability	55
3.12	Example	56
3.13	Conclusion	57
	References	58
<b>4</b>	<b>Establishment of Measurement Requirements – Performance-Based Specifications</b>	<b>59</b>
	<i>Todd L. Cecil</i>	
4.1	Introduction	59
4.2	Intended Purpose	60
4.3	Identification	60
4.4	Assay	62
4.4.1	Precision	62
4.4.2	Accuracy	63
4.4.3	Precision and Accuracy	64
4.4.3.1	Relationship between Accuracy and Precision	64
4.4.4	Specificity	65
4.4.4.1	Chromatographic Procedures	65
4.4.4.2	Non-chromatographic Procedures	66
4.4.5	Linearity and Range	67
4.4.5.1	Linearity	67
4.4.5.2	Range	67
4.5	Impurities	68
4.6	Limit Tests	69
4.6.1	Limit of Detection	69
4.6.2	Precision	70
4.6.3	Specificity	70
4.7	Quantitative Tests	70
4.7.1	Accuracy	70
4.7.2	Precision	71
4.7.3	Specificity and Range	71
4.8	Summary	71
	References	71
<b>5</b>	<b>Method Performance Characteristics</b>	<b>73</b>
	<i>Joachim Ermer</i>	
5.1	Introduction	73
5.2	Precision	74
5.2.1	Distribution of Data	74
5.2.1.1	The Normal Distribution and its Parameters	74
5.2.1.2	Robust Parameter	84
5.2.2	Precision Levels	84
5.2.2.1	System or Instrument Precision	85
5.2.2.2	Repeatability	86

5.2.2.3	Intermediate Precision and Reproducibility	86
5.2.3	Calculation of Precisions and Variances	89
5.2.3.1	Analysis of Variances (ANOVA)	90
5.2.3.2	Calculation of Precision from Linear Regression	92
5.2.4	Concentration Dependency of Precision	93
5.2.5	Precision Acceptance Criteria	95
5.2.5.1	Precision of the Reportable Result	95
5.2.5.2	Optimization of the Calibration Format	97
5.2.5.3	Acceptable Precision for Assay	101
5.2.5.4	Acceptable Precision for Impurities and Minor Components	105
5.2.6	Precisions Benchmarks	107
5.2.6.1	Precisions for LC Assay	108
5.2.7	Sources to Obtain and Supplement Precisions	116
5.2.7.1	Precisions from Stability	117
5.2.8	Precision Highlights	119
5.3	Accuracy and Range	119
5.3.1	Drug Substance	122
5.3.1.1	Significance Tests	122
5.3.1.2	Equivalence Tests	124
5.3.1.3	Direct Comparison	125
5.3.1.4	Comparison Examples	125
5.3.2	Drug Product	126
5.3.2.1	Percentage Recovery	127
5.3.2.2	Recovery Function	128
5.3.2.3	Standard Addition	128
5.3.2.4	Accuracy of Drug Product by Comparison	129
5.3.3	Impurities/Degradants	129
5.3.3.1	Recovery of Spiked Impurities	129
5.3.3.2	Accuracy of the Integration Mode	130
5.3.3.3	Response Factors	131
5.3.4	Acceptance Criteria (ATP Requirements)	132
5.3.4.1	Can this Theoretically Obtained Relationship be Supported by Experimental Results?	135
5.3.5	Joint Evaluation of Accuracy and Precision	136
5.3.6	Accuracy Highlights	137
5.4	Specificity	137
5.4.1	Demonstration of Specificity by Accuracy	140
5.4.2	Chromatographic Resolution	140
5.4.3	Peak Purity (Co-elution)	141
5.4.3.1	Rechromatography	141
5.4.3.2	Diode Array Detection	142
5.4.3.3	LC-MS	143
5.4.4	Specificity Highlights	145
5.5	Linearity	145
5.5.1	Unweighted Linear Regression	147

5.5.1.1	Graphical Evaluation of Linearity	151
5.5.1.2	Numerical Regression Parameters	153
5.5.1.3	Statistical Linearity Tests	155
5.5.1.4	Evaluation of the Intercept (Absence of Systematic Errors)	158
5.5.2	Weighted Linear Regression	160
5.5.3	Appropriate Calibration Models	162
5.5.4	Nonlinear and Other Regression Techniques	162
5.5.5	Linearity Highlights	163
5.6	Detection and Quantitation Limit	164
5.6.1	Requirements in Pharmaceutical Impurity Determination	164
5.6.1.1	Intermediate Quantitation Limit	166
5.6.1.2	General Quantitation Limit	166
5.6.2	Approaches Based on the Blank	167
5.6.3	Determination of DL/QL from Linearity	167
5.6.3.1	Standard Deviation of the Response	169
5.6.3.2	95% Prediction Interval of the Regression Line	171
5.6.3.3	Approach Based on German Standard DIN 32645	172
5.6.3.4	From the Relative Uncertainty	173
5.6.4	Precision Based Approaches	174
5.6.5	Comparison of the Various Approaches	175
5.6.6	Quantitation Limit Highlights	176
5.7	Glossary	177
	Acknowledgments	182
	References	182
<b>6</b>	<b>Method Design and Understanding</b>	<b>191</b>
6.1	Method Selection, Development, and Optimization	191
	<i>Melissa Hanna-Brown, Roman Szucs, and Brent Harrington</i>	
6.1.1	Introduction	191
6.1.2	Method Selection	192
6.1.3	Method Development	194
6.1.4	Method Optimization	205
	Acknowledgments	217
6.2	Analytical Quality by Design and Robustness Investigations	217
	<i>Rosario LoBrutto</i>	
6.2.1	Introduction	217
6.2.2	Method Validation Requirements	220
6.2.3	Robustness	221
6.2.4	Analytical Quality by Design	223
6.2.5	Design of Experiments (DOE)	225
6.2.6	FMEA (Failure Mode Effect Analysis)	227
6.2.7	Illustrative Case Study	231
6.2.8	Illustrative Example for Statistical Analysis	234
6.2.9	Control Strategy	239
6.2.10	Conclusions	240

	Acknowledgments	241
6.3	Case Study: Robustness Investigations	241
	<i>Gerd Kleinschmidt</i>	
6.3.1	Introduction	241
6.3.2	General Considerations in the Context of Robustness Testing	242
6.3.2.1	Basic and Intrinsic Parameters	243
6.3.3	Examples of Computer-Assisted Robustness Studies	245
6.3.3.1	Robustness Testing Based on Chromatography Modeling Software	246
6.3.3.2	Robustness Testing Based on Experimental Design	258
	Acknowledgments	287
6.4	System Suitability Tests	287
	<i>Joachim Ermer</i>	
6.4.1	Chromatographic System Suitability Parameters	288
6.4.1.1	Signal-to-Noise Ratio	289
6.4.1.2	Test for Required Detectability	291
6.4.1.3	Injection Precision	292
6.4.1.4	System Precision for Impurities?	293
6.4.2	Non-chromatographic System Suitability Parameters	293
6.4.3	Design of System Suitability Tests	294
	References	295
<b>7</b>	<b>Method Performance Qualification</b>	<b>303</b>
7.1	Introduction	303
	<i>Joachim Ermer</i>	
7.1.1	Example of a Precision Study	305
7.2	Case Study: Qualification of an HPLC Method for Identity, Assay, and Degradation Products	308
	<i>Gerd Kleinschmidt</i>	
7.2.1	Introduction	308
7.2.2	Experimental	310
7.2.3	Qualification Summary	310
7.2.4	Qualification Methodology	314
7.2.4.1	Specificity	314
7.2.4.2	Linearity	314
7.2.4.3	Accuracy	318
7.2.4.4	Precision	320
7.2.4.5	Quantitation Limit	321
7.2.4.6	Range	323
7.2.5	Conclusion	324
7.3	Design and Qualification of a Delivered Dose Uniformity Procedure for a Pressurized Metered Dose Inhaler	324
	<i>Andy Rignall</i>	
7.3.1	Introduction	324
7.3.1.1	Analytical Procedures for Complex Dosage Forms	324

7.3.1.2	Human and Environmental Factors Associated with Complex Laboratory Procedures	325
7.3.1.3	Delivered Dose Uniformity Testing for Inhalation Products	325
7.3.2	Designing a Delivered Dose Uniformity Procedure that will Meet an ATP	326
7.3.2.1	Risk Assessment and Classification	327
7.3.2.2	Noise Factors Associated with Dose Collection	331
7.3.2.3	Dose Recovery and Sample Preparation	333
7.3.2.4	Automated Delivered Dose Uniformity Procedure	333
7.3.2.5	Results Calculation and Reporting	334
7.3.3	Performance Characteristics of the Delivered Dose Uniformity Procedure	334
7.3.4	Qualification of the Delivered Dose Uniformity Procedure	335
7.3.5	Summary of the Analytical Control Strategy for a Delivered Dose Uniformity Procedure	336
	Acknowledgment	337
7.4	Implementation of Compendial/Pharmacopeia Test Procedures	337
	<i>Pauline McGregor</i>	
7.4.1	Background of Pharmacopeia Procedures	337
7.4.2	How Pharmacopeia Methods are Generated and Published	338
7.4.3	Challenges with Compendial Procedures and the Need to Verify	338
7.4.4	Using Pharmacopeia Procedures in a Laboratory for the First Time	339
7.4.5	Current Approach to Verification of Pharmacopeia Procedures	339
7.4.6	Integration of the Current Verification Process and the Lifecycle Approach	340
7.4.7	Implementation of a Pharmacopeia Procedure Using the Lifecycle Approach	341
7.4.7.1	Gather Knowledge	341
7.4.7.2	Finalizing the ATP	346
7.4.8	Performance Qualification	347
7.4.9	Conclusion	348
7.5	Transfer of Analytical Procedures	348
	<i>Christophe Agut and Joachim Ermer</i>	
7.5.1	Transfer Process and Strategy	349
7.5.1.1	Regulatory and International Guidance	349
7.5.1.2	Transfer Process	350
7.5.2	Comparative Testing	355
7.5.2.1	Equivalence-Based Methodology	355
7.5.2.2	Direct Comparison	369
	Acknowledgments	372
	References	372

<b>8</b>	<b>Continued Method Performance Verification</b>	<b>377</b>
	<i>Phil Nethercote and Christopher Burgess</i>	
8.1	Introduction	377
8.2	Routine Monitoring	377
8.2.1	Introduction	377
8.2.2	Establishing a Control Chart	380
8.2.3	Examples of Application of Control Charting to Analytical Procedures	382
8.2.3.1	Example 1	382
8.2.3.2	Example 2	382
8.2.4	Periodic Review	383
8.2.5	Determination of Root Cause Using CuSum Analysis	385
8.3	Investigating and Addressing Aberrant Data	391
8.3.1	Laboratory Failure Investigation	391
8.3.2	Classification of Atypical or Aberrant Results	393
8.3.3	Statistical Outlier Tests for Out-of-Expectation Results	399
8.3.4	Summary	405
8.4	Continual Improvement	406
8.4.1	Introduction	406
8.4.2	Control of Change	406
8.4.2.1	Risk Assessment of Changes	407
	References	409
	<b>Index</b>	<b>411</b>